Skip to main content

Table 1 Summary of various NIR-II hollow nanoplatforms for photothermal-based cancer theranostics (PTT refers to NIR-II PTT)

From: Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment

Material

Templates and mechanisms

NIR-II PTAs and PCE

Tumor model

Biomedical applications

Reference

HPP

SiO2

HPP; 45.1%

4T1 tumor

PTT

[97]

Ag2S Ve

self-assembly

Ag2S QDs; —

4T1 tumor

NIR-II FLI and PTT

[98]

AuHNRs-DTPP

Te nanorods

AuHNRs;

H22 tumor

FLI and PTT/PDT

[99]

AAM-Ce6

galvanic replacement reaction

AAM-Ce6; 52.5%

HeLa tumor

PAI/FLI/MRI and PTT/PDT

[100]

TAT-Pd@Au/Ce6/PAH/H-MnO2

mSiO2

TAT-Pd@Au; 56.9%

MCF-7 tumor

T1-weighted MRI and PTT/PDT

[101]

AuHNRs-DOX

Se-doped Te nanorod

AuHNRs; 33%

SCC-7 tumor

PAI/CT imaging and PTT/chemotherapy

[102]

NiP PHNPs-DOX

HCl solution etching

NiP PHNPs; 56.8%

U14 tumor

T1-weighted MRI/PAI and PTT/chemotherapy

[103]

DSF@PEG-HCuS

nanoscale Kirkendall effect

DSF@PEG-HCuS; 23.8%

4T1 tumor

PAI and PTT/chemotherapy

[104]

PEG-Cu2Se HNCs

anion exchange method

Cu2Se HNCs; 50.89%

4T1 tumor

PTT/CDT

[105]

HSC-2

nano-Beta zeolite

HSC-2; 41.41%

4T1 tumor

NIR-II PAI/FLI and PTT/catalytic therapy

[106]

HC-AB

beta zeolite

HC-AB; 25.45%

4T1 tumor

NIR-II PAI and PTT/gas therapy

[107]

DOX@H-Cu9S8/PEG

nanoscale Kirkendall effect

H-Cu9S8; 40.9%

CT26 tumor

NIR-II PAI and PTT/CDT/chemotherapy

[108]

HMNC

Ostwald ripening process

HMNC; 36.3%

HeLa tumor

T2-weighted MRI and PTT/CDT/chemotherapy

[109]

CPT-RHNS-PGEA/p53

SiO2-RF-1

RHNS-PGEA; 59.2%

4T1 tumor

PAI and PTT/chemo/gene therapy

[110]

PEG-CMS@GOx

nanoscale Kirkendall effect

CMS; 63.3%

U14 tumor

PTT/PDT/CDT/ST/ immunotherapy

[111]